ArticleCancers2025
Refining Risk Stratification and Surveillance Strategies in Pleuropulmonary Solitary Fibrous Tumors-An International, Retrospective, Multicenter Analysis.
Article in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Perioperative Decision-Making for a Solitary Fibrous Tumor of the Pleura: Lessons from Two Cases and Current Evidence.Diagnostics (Basel, Switzerland) · 2026Article
- Pelvic solitary fibrous tumors: clinical manifestations, surgical management and long-term outcomes.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSolitary fibrous tumor of the pleura are rare neoplasms, and follow-up protocol is lacking. Various risk stratification systems have been proposed to predict recurrence. The aim of this study is to evaluate common risk scores and risk factors leading to a recommendation for follow-up frequency.
methodsWe pooled data as part of a multicenter international study with the participation of eight centers in Germany, Switzerland, Denmark, and Austria. Kaplan-Meier survival-curves were used comparing several risk stratification system(s). A Log-rank test was performed to analyze prognostic clinical and pathological factors affecting overall and recurrence-free survival.
resultsWe included 155 patients from 2004 to 2024: 52.3% were male, median age was 64 years (range 32 to 89). Recurrence rate was 17.4% with median recurrence-free survival of 131 months. Mean time to recurrence was 64.4 (range 9-151) months. Analysis showed that age, tumor morphology, necrosis, and increased mitotic activity were independent prognostic factors for RFS.
conclusionsThe WHO risk stratification system demonstrated the highest discriminatory power for recurrence-free survival in the Kaplan-Meier analyses, indicating that the WHO classification remains the most accurate predictor to date. We modified the commonly used risk systems to achieve improved stratification into low-, intermediate- and high-risk groups. The occurrence of late recurrences underscores the need for long-term follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.